U.S.-based biotech company Kure Cells has secured USD 10 million in a Series A funding round led by Wa’ed Ventures, the venture capital arm of Aramco.
The round also saw participation from Komel Healthcare, NantBio, and several U.S. investors under the US93 group.
In addition, Saudi Arabia’s Qomel Co. contributed USD 1.38 million to the round, part of its broader strategy to invest in next-generation therapeutic technologies.
The move reinforces Saudi Arabia’s ambition, through the Ministry of Investment and the Research, Development, and Innovation Authority (RDIA), to become a regional hub for biotechnology and life sciences research.
How Kure Cells is expanding biotech innovation into Saudi Arabia
With this new capital, Kure Cells plans to expand its footprint into Saudi Arabia, establishing research, development, and manufacturing facilities within the Kingdom.
The company also aims to collaborate with local scientists and institutions to adapt its proprietary “Ultra-Fast CAR” (UF-CAR) platform to regional healthcare needs.
Go deeper on GCC & Africa tech — $9.99/month.
Deep dives and investor insights the free digest doesn't cover.
Founded by David Wald and Sayer Alfuraydi, Kure Cells specializes in advanced cell therapies designed to accelerate patient treatment.
Its UF-CAR technology enables same-day engineering of patient T-cells in under 24 hours, a dramatic improvement over the traditional multi-week process used in CAR-T therapy manufacturing.
“Their rapid cell therapy manufacturing platform compresses timelines, lowers costs, and broadens patient access while actively building Saudi’s biotech ecosystem through local R&D, talent development, and clinical translation,” said Anas Algahtani, Acting CEO of Wa’ed Ventures.
Kure Cells’ expansion marks a key step in Saudi Arabia’s growing biotechnology push, supporting national efforts to localize innovation, attract global R&D partnerships, and build a sustainable biotech value chain that strengthens healthcare resilience across the region.
Engagement